These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 16959618)

  • 21. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.
    Oostenbrink JB; Rutten-van Mölken MP; Al MJ; Van Noord JA; Vincken W
    Eur Respir J; 2004 Feb; 23(2):241-9. PubMed ID: 14979498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease.
    Calverley PM; Lee A; Towse L; van Noord J; Witek TJ; Kelsen S
    Thorax; 2003 Oct; 58(10):855-60. PubMed ID: 14514937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.
    van Noord JA; Aumann JL; Janssens E; Smeets JJ; Verhaert J; Disse B; Mueller A; Cornelissen PJ
    Eur Respir J; 2005 Aug; 26(2):214-22. PubMed ID: 16055868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tiotropium: a potential replacement for ipratropium in patients with COPD.
    Shukla VK
    Issues Emerg Health Technol; 2002 Jul; (35):1-4. PubMed ID: 12195603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group.
    Maesen FP; Smeets JJ; Sledsens TJ; Wald FD; Cornelissen PJ
    Eur Respir J; 1995 Sep; 8(9):1506-13. PubMed ID: 8575576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
    Vincken W; van Noord JA; Greefhorst AP; Bantje TA; Kesten S; Korducki L; Cornelissen PJ;
    Eur Respir J; 2002 Feb; 19(2):209-16. PubMed ID: 11871363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
    Decramer ML; Chapman KR; Dahl R; Frith P; Devouassoux G; Fritscher C; Cameron R; Shoaib M; Lawrence D; Young D; McBryan D;
    Lancet Respir Med; 2013 Sep; 1(7):524-33. PubMed ID: 24461613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
    Caillaud D; Le Merre C; Martinat Y; Aguilaniu B; Pavia D
    Int J Chron Obstruct Pulmon Dis; 2007; 2(4):559-65. PubMed ID: 18268929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study.
    Vogelberg C; Engel M; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Downie J; Nething K; Vevere V; Vandewalker M
    Respir Med; 2014 Sep; 108(9):1268-76. PubMed ID: 25081651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease].
    Baloira Villar A; Vilariño Pombo C
    Arch Bronconeumol; 2005 Mar; 41(3):130-4. PubMed ID: 15766465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
    Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tiotropium Respimat inhaler and the risk of death in COPD.
    Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
    N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
    Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of short-acting bronchodilators added to maintenance tiotropium therapy.
    Kerstjens HA; Bantje TA; Luursema PB; Sinninghe Damste HE; de Jong JW; Lee A; Wijker SP; Cornelissen PJ
    Chest; 2007 Nov; 132(5):1493-9. PubMed ID: 17890476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
    Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
    Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.
    Bateman ED; Tashkin D; Siafakas N; Dahl R; Towse L; Massey D; Pavia D; Zhong NS
    Respir Med; 2010 Oct; 104(10):1460-72. PubMed ID: 20620037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease.
    Hohlfeld JM; Sharma A; van Noord JA; Cornelissen PJ; Derom E; Towse L; Peterkin V; Disse B
    J Clin Pharmacol; 2014 Apr; 54(4):405-14. PubMed ID: 24165906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.
    Ichinose M; Takizawa A; Izumoto T; Tadayasu Y; Hamilton AL; Kunz C; Fukuchi Y
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1673-83. PubMed ID: 26316741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD.
    Casaburi R; Kukafka D; Cooper CB; Witek TJ; Kesten S
    Chest; 2005 Mar; 127(3):809-17. PubMed ID: 15764761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
    Verkindre C; Fukuchi Y; Flémale A; Takeda A; Overend T; Prasad N; Dolker M
    Respir Med; 2010 Oct; 104(10):1482-9. PubMed ID: 20541381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.